lapatinib has been researched along with nsc319726 in 1 studies
Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (nsc319726) | Trials (nsc319726) | Recent Studies (post-2010) (nsc319726) |
---|---|---|---|---|---|
1,919 | 305 | 1,442 | 8 | 0 | 8 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Díaz-Gil, L; Díaz-Rodríguez, E; Gandullo-Sánchez, L; Ocaña, A; Pandiella, A; Ríos-Luci, C | 1 |
1 other study(ies) available for lapatinib and nsc319726
Article | Year |
---|---|
Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms.
Topics: Animals; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; DNA Damage; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Imidazoles; Lapatinib; Mice; Naphthoquinones; Protein Kinase Inhibitors; Pyridines; Quinolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2020 |